DREAMM-7
The trial that brought the withdrawn myeloma ADC back, beating a daratumumab-based standard on progression and survival.
PFS 36.6 vs 13.4 months (HR 0.41); OS HR 0.58 (2024 update). Ocular events in ~80% (grade 3+ ~35%) managed by dose holds. Re-approved US and EU 2025 (US label restricted to Pd combination initially after ODAC concerns on dosing).
- Median 36.6 vs 13.4 months with Belantamab-Vd compared with Dara-Vd; about 23.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 59 percent lower chance of the event at any given time (hazard ratio 0.41, likely range 0.31 to 0.53).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- The treated group had about 42 percent lower chance of the event at any given time (hazard ratio 0.58).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Relapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
494 participants enrolled.
Numbers not yet public.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (median)primary | Belantamab-Vd | 243 | 36.6 months | 0.41 (0.31–0.53) | — | link |
| Dara-Vd | 251 | 13.4 months | ||||
| Overall survival | Belantamab-Vd | — | — | 0.58 (0.43–0.79) | — | — |
| Dara-Vd | — | — |
Pages like this
not linked directly; found by shared links- TrialDREAMM-8
Shares Belantamab mafodotin, Multiple myeloma.
- PersonPaul G. Richardson
Shares Bortezomib, Multiple myeloma.
- PersonKenneth C. Anderson
Shares Bortezomib, Multiple myeloma.
- PersonSundar Jagannath
Shares Bortezomib, Multiple myeloma.
- TrialCEPHEUS
Shares Bortezomib, Multiple myeloma.
- TrialIMROZ
Shares Bortezomib, Multiple myeloma.
- TermProteasome inhibitor (bortezomib, carfilzomib, ixazomib)
Shares Bortezomib, Multiple myeloma.
- TrialPERSEUS
Shares Bortezomib, Multiple myeloma.